Navigation Links
US Drugmaker Slapped Huge Fine for Misleading Doctors Over Addictive Painkiller

After four years of unrelenting pursuit by the Food and Drug Administration, the Purdue pharma of the US gave in, admitting it had made false claims about their popular painkiller Oxycontin.

They have agreed to pay up $634.5 millions for making false claims about the drug to boost sales and also pleaded guilty to charges of playing down Oxycontins addictive and euphoric properties.

Purdue pleaded guilty to a felony count of misbranding a drug with intent to defraud and mislead.

Under the agreement, it will pay a $600 million settlement, including a criminal fine, restitution to government agencies, and more than $276 million in forfeiture. In a separate civil settlement, Purdue will pay $100.6 million.

According to an investigation by the Food and Drug Administration (FDA)s Office of Criminal Investigations (OCI), the drug company trained its sales force to represent OxyContin as a drug that did not cause euphoria and was less addictive than immediate-release opiates; and allowed healthcare providers to have the mistaken notion that OxyContin was less addictive than morphine.

Over the last few years there have been instances of hundreds of overdose deaths linked to OxyContin's main ingredient oxycodone. The drug was marketed as a miracle pain reliever; less addictive and less subject to abuse than similar medications. However, it was later found that its contents could be highly addictive and even fatal.

Purdue Pharma also made false representations about the difficulty of extracting oxycodone, the active ingredient, from the OxyContin tablet, and labeled the drug as providing fewer peaks and valleys than with immediate-release oxycodone, the OCI said.

U.S. Attorney John Brownlee said, "With its OxyContin, Purdue unleashed a highly abusable, addictive, and potentially dangerous drug on an unsuspecting and unknowing public."

"For these misrepresentations and crimes, Purdue a nd its executives have been brought to justice."

OxyContin is a trade name for oxycodone, and is a time-release painkiller that can be highly addictive. In that variety the ingredients are released over a period of time for sustained effect.

The drug is meant to be swallowed whole and digested over 12 hours. It was later found that the pills can produce a heroin-like high if crushed and then swallowed, snorted or injected.

According to the Drug Enforcement Agency (DEA), the number of deaths linked to the use of OxyContin jumped 400 percent between 1996 and 2001. Still, in 2001, Purdue executives testified they had just become aware that the drug was being abused.

In its statement, Purdue Pharma said it accepted responsibility for false statements made about the drug's risks of addiction, abuse, withdrawal and tolerance six years ago, but added, "during the past six years, we have implemented changes to our internal training, compliance and monitoring systems that seek to assure that similar events do not occur again."

Generic firms, including Teva and Endo, had sold generic versions of Oxycontin, but have since stopped making the products and are not accused of any wrongdoing in connection with promoting their products, reports said.


'"/>




Related medicine news :

1. Misleading anti-malarial drug
2. Misleading Advertisements for Prescription Drugs
3. The Effects Of Smoking Misleading
4. Lifting The Screen off Misleading Sunscreen labels
5. Misleading Health Claims On Food Labels No Longer Allowed in EU
6. Walkers Crisps Advertisements make Misleading Claims about Salt Content
7. Medical Council Of India Draws Public Attention on Misleading Ads.
8. Obesity Drug Advertisements Misleading Teens
9. Labeling of Dairy Products with Trans fat labels, Misleading to Consumers
10. WHO Condemns Tobacco Industry for Misleading Public
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology: